JP2020186248A5 - - Google Patents

Download PDF

Info

Publication number
JP2020186248A5
JP2020186248A5 JP2020128994A JP2020128994A JP2020186248A5 JP 2020186248 A5 JP2020186248 A5 JP 2020186248A5 JP 2020128994 A JP2020128994 A JP 2020128994A JP 2020128994 A JP2020128994 A JP 2020128994A JP 2020186248 A5 JP2020186248 A5 JP 2020186248A5
Authority
JP
Japan
Prior art keywords
antibody
seq
polypeptide
bispecific antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020128994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020186248A (ja
JP7003347B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020186248A publication Critical patent/JP2020186248A/ja
Publication of JP2020186248A5 publication Critical patent/JP2020186248A5/ja
Priority to JP2021150755A priority Critical patent/JP7241827B2/ja
Application granted granted Critical
Publication of JP7003347B2 publication Critical patent/JP7003347B2/ja
Priority to JP2023035060A priority patent/JP7635285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020128994A 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 Active JP7003347B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021150755A JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562099236P 2015-01-02 2015-01-02
US62/099,236 2015-01-02
US201562200363P 2015-08-03 2015-08-03
US62/200,363 2015-08-03
US201562261609P 2015-12-01 2015-12-01
US62/261,609 2015-12-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017534345A Division JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021150755A Division JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2020186248A JP2020186248A (ja) 2020-11-19
JP2020186248A5 true JP2020186248A5 (enExample) 2021-04-30
JP7003347B2 JP7003347B2 (ja) 2022-02-04

Family

ID=56285069

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017534345A Active JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2020128994A Active JP7003347B2 (ja) 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2021150755A Active JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A Active JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017534345A Active JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021150755A Active JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A Active JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Country Status (13)

Country Link
US (2) US11390687B2 (enExample)
EP (2) EP3240570B1 (enExample)
JP (4) JP6744313B2 (enExample)
KR (2) KR102670705B1 (enExample)
CN (2) CN114316061B (enExample)
AU (2) AU2015373910B2 (enExample)
CA (1) CA2972800A1 (enExample)
CO (1) CO2017007123A2 (enExample)
EA (1) EA201791527A1 (enExample)
IL (2) IL253180B2 (enExample)
MX (2) MX2017008541A (enExample)
NZ (1) NZ771568A (enExample)
WO (1) WO2016109774A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL253180B2 (en) 2015-01-02 2023-04-01 Dyax Corp Bispecific antibodies against plasma kallikrein and factor xii
KR102794955B1 (ko) * 2015-07-21 2025-04-15 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
JP7319916B2 (ja) * 2016-09-16 2023-08-02 武田薬品工業株式会社 遺伝性血管性浮腫のｒｎａバイオマーカー
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
KR20200037388A (ko) * 2017-08-16 2020-04-08 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
CN111727201A (zh) * 2017-10-18 2020-09-29 再生生物股份有限公司 完全人源翻译后修饰的抗体治疗剂
WO2019140320A1 (en) * 2018-01-12 2019-07-18 Genzyme Corporation Methods for the quantitation of polypeptides
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
KR20210025046A (ko) * 2018-06-08 2021-03-08 가부시키가이샤 모달리스 개변된 Cas9 단백질 및 그의 용도
AU2019299935A1 (en) * 2018-07-11 2021-02-18 Inc. Momenta Pharmaceuticals Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to PD-L1
CN112789291A (zh) * 2018-08-08 2021-05-11 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
KR20250112921A (ko) * 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
CN114375302B (zh) * 2019-07-26 2024-12-24 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
EP4236974A2 (en) * 2020-10-29 2023-09-06 RegenxBio Inc. Vectorized factor xii antibodies and administration thereof
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
WO2022156799A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
WO2024238407A2 (en) * 2023-05-12 2024-11-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE227979T1 (de) 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
CA2364484A1 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN101260156A (zh) * 2002-06-28 2008-09-10 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
JP5118492B2 (ja) 2004-12-23 2013-01-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血栓の形成の防止および／または安定化の防止
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TR201904662T4 (tr) 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
FI2734552T3 (fi) * 2011-07-22 2025-02-12 Csl Behring Gmbh Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
JP6271251B2 (ja) * 2011-10-05 2018-01-31 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
HRP20201004T1 (hr) * 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
HRP20190528T1 (hr) * 2013-01-20 2019-05-17 Dyax Corp. PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
US20160166660A1 (en) * 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
DK3406633T3 (da) 2013-07-25 2022-03-28 Cytomx Therapeutics Inc Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
IL253180B2 (en) 2015-01-02 2023-04-01 Dyax Corp Bispecific antibodies against plasma kallikrein and factor xii
KR102794955B1 (ko) 2015-07-21 2025-04-15 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
EP3263803B1 (en) 2016-06-30 2019-08-14 ABB Schweiz AG Substation

Similar Documents

Publication Publication Date Title
JP2020186248A5 (enExample)
JP2018502572A5 (enExample)
JP7209464B2 (ja) ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体
CN110831626B (zh) 单价抗备解素抗体及抗体片段
CN108610421B (zh) Cx3cr1结合多肽
JP2020031650A (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
US11384141B2 (en) Serum albumin binding antibodies for tuneable half-life extension of biologics
JP2021191789A (ja) 抗補体Ｂｂ因子抗体及びその使用
JP7189211B2 (ja) 血清中のタンパク質の半減期を増加させるための組成物及び方法
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
CN108610418A (zh) 抗补体C1s抗体和其用途
EP3019192A2 (en) Compositions and methods for increasing protein half-life in a serum
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
KR20220044748A (ko) 4가 대칭 이중 특이적 항체
JP7797203B2 (ja) 抗ｇａｌ９免疫阻害性結合分子
RS55775B2 (sr) Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
EP4421095A1 (en) Anti-mesothelin nanobodies and use thereof
CA3218571A1 (en) Methods of screening and expression of disulfide-bonded binding polypeptides
CN102257009A (zh) 具有针对dc-sign的结合特异性的配体
US20230227536A1 (en) Immunogenicity-reduced low-molecular antibody and method for producing same
US20230265187A1 (en) Anti-tigit antibody and methods of use thereof
JP2022537672A (ja) 抗ｂ７－ｈ３抗体およびその使用方法
Aoki Development of Mirror-Image VHHs with Less Immunogenicity